SPRBライブシグナル | Getagraph.comで利益を最大化

売る 109204 min ago

@ $4.51

発行日: 14 2月 2024 @ 05:35

リターン: -84.28%

前回のシグナル: 2月 13 - 23:31

前回のシグナル: 買う

リターン: 4.64 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:39):

Stats
本日の出来高	215 042
平均出来高	1.36M
時価総額	29.17M
EPS	$0 ( 2024-03-21 )
次の収益日	( $-0.320 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.570
ATR14	$0.00300 (0.42%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Novo Holdings A/s	Sell	465 021	COMMON STOCK
2024-03-18	Novo Holdings A/s	Sell	842 020	COMMON STOCK
2024-03-19	Novo Holdings A/s	Sell	593 000	COMMON STOCK
2024-03-20	Novo Holdings A/s	Sell	359 979	COMMON STOCK
2024-03-14	Novo Holdings A/s	Sell	1 912 316	COMMON STOCK

INSIDER POWER
2.69
Last 98 transactions
Buy: 11 294 782 \| Sell: 4 967 660

ボリューム相関

長: 0.15 (neutral)

短: -0.70 (moderate negative)

Signal:(56.344) Neutral

Spruce Biosciences, Inc. 相関

10 最も正の相関
DYNT	0.967
DGLY	0.954
FTFT	0.94
SLNO	0.94
SYKE	0.929
CVV	0.927
LIVE	0.925
CSWI	0.923
FELE	0.922
IPHA	0.921

10 最も負の相関
MTEX	-0.906
LCAP	-0.905
AHPI	-0.899
NAKD	-0.887
PROC	-0.883
LAWS	-0.88
VERA	-0.872
GRPH	-0.869
OP	-0.868
TRIT	-0.868

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Spruce Biosciences, Inc. 相関 - 通貨/商品

-0.32
( neutral )

0.00
( neutral )

0.23
( neutral )

Spruce Biosciences, Inc. 財務諸表

Annual	2023
収益:	$10.09M
総利益:	$10.02M (99.31 %)
EPS:	$-1.240

FY	2023
収益:	$10.09M
総利益:	$10.02M (99.31 %)
EPS:	$-1.240

FY	2022
収益:	$0
総利益:	$-429 000 (0.00 %)
EPS:	$-1.920

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.813

Financial Reports:

No articles found.

Spruce Biosciences, Inc.

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.